Phase 3 IMVT-1402 trial advancing in plans, with March as goal
By March, Immunovant plans to initiate four or five pivotal clinical trials of its lead therapeutic candidate IMVT-1402…
Articles by Lindsey Shapiro, PhD
Treatment with CAR T-cell therapy seen to reduce gMG severity in trial
Treatment with the investigational CAR T-cell therapy Descartes-08 led to deep and sustained reductions in disease severity among generalized…
Immunovant positions IMVT-1402 as lead MG treatment candidate
Immunovant plans to prioritize development of its newer treatment candidate, IMVT-1402, over its Phase 3 candidate, batoclimab, for…
CAR T-cell therapy Descartes-08 receives RMAT status from FDA
Cartesian Therapeutics’ investigational cell therapy Descartes-08 has been granted regenerative medicine advanced therapy (RMAT) designation by the U.S. Food…
Azathioprine, MMF effective, but more studies needed: PROMISE-MG
No significant differences in clinical outcomes or quality of life were observed between myasthenia gravis (MG) patients treated with…
Rystiggo, Zilbrysq cleared in UK for adults with generalized MG
Regulators in the U.K. have approved UCB’s Rystiggo (rozanolixizumab) as an add-on treatment for adults with generalized myasthenia…
MDA 2024: Benefits of Zilbrysq sustained over 1 year in gMG study
Clinical responses to the approved generalized myasthenia gravis (gMG) therapy Zilbrysq (zilucoplan) have now been sustained for more than…
MDA 2024: Vyvgart Hytrulo eases disease severity, boosts life quality
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) consistently reduced disease severity and improved quality of life across treatment cycles among…
Curcumin herbal therapy found to ease disease severity in MG mice
Curcumin therapy — treatment with the traditional Asian medicine, which is the main ingredient in the spice turmeric — was…
IVMP, tacrolimus may help OMG symptoms where oral steroids don’t
Both high-dose intravenous methylprednisolone (IVMP) and tacrolimus effectively reduced symptom severity in patients with ocular myasthenia gravis (OMG) who…